Axsome Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 10-Q, Quarterly reportAug 10 →InsidersNo open-market buys. 8 insiders sold $112.9M, all 31 sales on a 10b5-1 plan.→HoldersBlackRock 5.9%Vanguard Portfolio 3.8%Vanguard 3.8%→Financing →PeersClosest companies: XERS, ALT, SPRO→
From the filings
Figures
- Revenue
- $776.6Mlast 12 months
- Net income
- −$191.6Mlast 12 months
- Operating cash flow
- −$70.7Mlast 12 months
- Cash and equivalents
- $319.9Mat the last balance sheet
- Total debt
- $188.0Mat the last balance sheet
- Shares outstanding
- 52.3M shareson issue